
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings Inc. demonstrates promising growth potential, highlighted by a projected revenue of $23 million for 2025, anchored in both its legacy enterprise business and the Indego Personal segment. Recent quarterly performance reflects a substantial 21%-24% quarter-over-quarter growth, suggesting a recovery and increased market engagement driven by a higher placement of EksoNR devices. The strategic partnership aimed at expanding the Indego market, combined with anticipated improvements in reimbursement processes, positions Ekso favorably for sustainable long-term revenue growth.
Bears say
Ekso Bionics Holdings Inc experienced a total revenue decline of 2% in 2024, totaling $17.9 million compared to $18.3 million in 2023, primarily due to decreased enterprise sales linked to irregularities in procurement cycles among integrated delivery networks. While there was notable revenue growth in Europe, particularly in France, it could not sufficiently counterbalance the overall revenue drop. Additionally, the significant loss on the revaluation of warrant liabilities raises concerns about the company's financial stability and future earnings potential, further contributing to a negative outlook.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares